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Teaching Lecture: Brachytherapy for the pelvic region: 
status and perspective for the future  
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Brachytherapy in gynaecological cancers, and especially in 
cervix cancer, has greatly evolved during the last twenty 
years. For decades, brachytherapy has relied on x-ray 
orthogonal acquisitions, and prescription has been a matter 
of systems and schools, making reporting and comparisons 
difficult. Based on the developments of afterloaders and 
treatment planning systems, image-guided adaptive 
brachytherapy has emerged. This high precision technique 
combines all modern radiation requirements: image 
guidance, adaptation to tumor response, and short time 
treatment.  
Ten years ago, the GEC-ESTRO, in a will of harmonizing 
practices, published recommendations in cervical cancers 
regarding the definition of target-volumes and the reporting. 
These recommendations were rapidly adopted worldwide. 
During the last decade, multiple monocentric series, 
historical cohorts’ comparisons, and a prospective 
multicentric study (STIC trial) demonstrated high local 
control rates with a limited morbidity in regard to classical 
data. These data are about to be confirmed by two large 
studies led by the Gyn GEC-ESTRO: Retro-EMBRACE and 
EMBRACE, which will establish MRI-guided brachytherapy as a 
gold standard.  
In addition, clear dose-volume effect relationships have been 
demonstrated between the modern dosimetric parameters 
and the probability of achieving local control or facing 
morbidity. The better knowledge of these correlations 
allowed the launch of EMBRACE II, a prospective study 
combing the best radiation modalities (EBRT and IGABT), 
with optimal and ambitious planning aims. In the near future, 
the large amount of data collected in the EMBRACE study (> 1 
500 patients accrued) will allow the development of 
monograms integrating not only dosimetric parameters, but 
also criteria on comorbidities, clinical features, and tumor 
response to external beam radiotherapy. This would be of 
great help in adapting and personalizing treatment plans.  
Longer-term prospects include the development of 
alternative image modalities for guidance, such as endorectal 
ultrasound, cheaper and more accessible than MRI, or 
conversely, a more advanced and sophisticated image 
modality.  
Image-guided brachytherapy is also progressively declined in 
other gynecologic tumors, such as vagina cancer or non-
operable endometrial cancer. 
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Prostate brachytherapy allows radiation dose escalation 
directly into the gland with minimal dose to adjacent rectum 
and bladder. Over the last decade improvements in 
brachytherapy technology have refined dose delivery with 
the introduction of HDR after loading devices, more 
sophisticated treatment planning systems and the 
incorporation of functional imaging into the planning process. 
This teaching lecture will provide an overview of the 
techniques, indications, and clinical outcomes for both 
permanent and High Dose Rate prostate brachytherapy. 
Recent results from randomised clinical trials will be 
critiqued and emerging indications including focal and 
salvage treatments discussed. 
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for coping with anatomical variations: hope or hype?  
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Introduction: Variation in shape, position and treatment 
response of both tumour and organs at risk are major 
challenges for accurate dose delivery in radiotherapy. 
Adaptive radiotherapy (ART) has been proposed to customise 
the treatment to these motion/response patterns of the 
individual patients, but increases workload thus challenge 
clinical implementation. This presentation presents a review 
of the clinically implemented ART in addition to in silico 
workflows that have been published on pelvic tumours.  
 
Material and methods: Initial identification of papers was 
based on searches in PubMed. For each tumour site (prostate, 
gynaecological [gynae], bladder, ano-rectal), the identified 
papers were screened independently by two researches for 
selection of studies describing all processes of an ART 
workflow: treatment monitoring and evaluation, decision and 
execution of adaptations. Both brachytherapy (BT) and 
external beam studies were eligible in the review.  
 
Result: The review consisted of 43 clinical studies and 51 in 
silico studies. For prostate, 1219 patients were treated with 
offline re-planning workflows, mainly to adapt prostate 
motion relative to bony anatomy. For gynae 1155 patients 
were treated with online BT re-planning while 25 ano-rectal 
cancer patients were treated with offline re-planning, all to 
account for tumour regression detected by MRI/CT. For 
bladder and gynae, 161 and 64 patients respectively, were 
treated with library-based online plan selection to account 
for target volume and shape variations (Figure). In 
comparison to non-ART, sparing of rectum (prostate and 
bladder cancer), bladder (ano-rectal cancer) and bowel 
cavity (gynae and bladder cancer) was reported with ART. 
